Pulmonx's FDA Nod: First To US Market With Endobronchial Valve System
Executive Summary
Pulmonx announced US FDA approval of its Zephyr endobronchial valve system for treating severe emphysema patients. This makes it the first minimally invasive device to be approved in the US for treating severe emphysema, a severe form of chronic obstructive pulmonary disease.
You may also be interested in...
Pulmonx Picks Up $86M IPO Plans After COVID-19 Disruption
The company originally filed to list on the NASDAQ in February but withdrew as the pandemic hit.
Global Device Approvals, Weekly Snapshot: June 25-July 1, 2018
A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker.
Pulmonx's Zephyr Data Bring NICE Thumbs-Up For Endobronchial Valves
The UK’s National Institute for Health and Care Excellence (NICE) is now recommending insertion of endobronchial valves used to treat severe emphysema, and the Interventional Procedures Advisory Committee that wrote the recommendations points out that most of the support for this procedure comes from trials of Pulmonx' Zephyr "duckbill" endobronchial valve.